Национальный цифровой ресурс Руконт - межотраслевая электронная библиотека (ЭБС) на базе технологии Контекстум (всего произведений: 610370)
Контекстум
Кардиология в Беларуси  / №2 2017

Ef ifcacy of combined antihypertensive treatment with aceinhibitor and i1-imidazoline receptor agonist in patients with metabolic syndrome (60,00 руб.)

0   0
Первый авторAlyavi
АвторыAlyavi B., Uzokov J.
Страниц1
ID609269
АннотацияBackground. Hypertension is the key component of the metabolic syndrome. Aim of this study was to assess ef cifacy of monotherapy with ACE inhibitor perindopril or I1-imidazoline receptor agonist moxonidine and their combination in patients with metabolic syndrome (MS)
Alyavi, A. Ef ifcacy of combined antihypertensive treatment with aceinhibitor and i1-imidazoline receptor agonist in patients with metabolic syndrome / A. Alyavi, B. Alyavi, J. Uzokov // Кардиология в Беларуси .— 2017 .— №2 .— С. 8-8 .— URL: https://rucont.ru/efd/609269 (дата обращения: 20.04.2025)

Предпросмотр (выдержки из произведения)

Материалы IХ Международной научно-практической конференции «Артериальная гипертензия и профилактика сердечно-сосудистых заболеваний» Alyavi A.1 , Alyavi B.,2 Uzokov J.1 1 Republican specialized scientifi c-practical medical center of therapy and medical rehabilitation, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan Tashkent, Uzbekistan 2 Effi cacy of combined antihypertensive treatment with aceinhibitor and i1-imidazoline receptor agonist in patients with metabolic syndrome Background. <...> Hypertension is the key component of the metabolic syndrome. <...> Aim of this study was to assess effi cacy of monotherapy with ACE inhibitor perindopril or I1-imidazoline receptor agonist moxonidine and their combination in patients with metabolic syndrome (MS). <...> Materials and methods. 63 moderate hypertensive patients with MS were enrolled in this study. <...> All patients were divided into 3 groups with 21 patients per group. <...> The fi rst group 5 mg perindopril, the second group 0.4 mg moxonidine and the third group 5 mg perindopril and 0.4 mg monoxidine were provided. <...> Anthropometric and laboratory analysis are measured at baseline and after 12 weeks. <...> In moderate hypertension BP normalized in 41% and 43% on monotherapy with perindopril or moxonidine, respectively, and in 84% patients given perindopril+moxonidine. <...> No changes of lipid profi le occurred in the fi rst group of patients while signifi cant elevation of high density lipoprotein cholesterol (p<0.05) and tendency to lowering of triglyceride level and LDL-C level were observed in second and third groups but insignifi cantly (p>0.05). <...> Combined treatment with perindopril and moxonidine is more eff ective than monotherapy with each of the above drugs in patients with metabolic syndrome. _________________________________________________________________________________________________ Gorshkov I., Volynkina A., Chernykh T. Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia Alpha-lipoic acid cytoprotective therapy in type 2 diabetes patients with arterial hypertension Aim. <...> To study alpha-lipoic acid (ALA) effi cacy in oxidative stress (OS) modifi cation in type 2 diabetes mellitus (T2DM) patients with diabetes polyneuropathy (DPN). <...> Neuropathic status (NS) indices: Neuropathy Symptoms Score (NSS), Total Symptoms Score (TSS), Neuropathy Disability Score (NDS), Douleur Neuropathique 4 <...>